Baxter reports Q3 adjusted EPS 80c, consensus 78c

Reports Q3 revenue $3.85B, consensus $3.85B. “Baxter (BAX) delivered positive performance in the third quarter of 2024, as the company continues to execute against its strategic transformation,” said Jose (Joe) E. Almeida, chair, president and chief executive officer. “The pending sale of our Kidney Care business represents another defining milestone in our ongoing transformation journey. We are also making substantial progress advancing hurricane recovery efforts at our North Cove, North Carolina, facility, thanks to the inspirational commitment and resilience of our Baxter team, in coordination with government agencies. While the hurricane’s aftermath is expected to have an impact on our near-term financial outlook, we remain confident in Baxter’s outlook and growth trajectory following completion of the pending Kidney Care sale.”